Biosimilars started to gain a firm foothold in the market this year and could take off in 2023 with the advent of Humira biosimilars. Our articles about biosimilars were some of the most viewed of the year.
Marcus Snow, M.D., chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
If biosimilar acceptance is to grow, it’s going to take a great deal of work to improve the levels of trust between payers, patients, and oncologists.
Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the U.S. market.